789 – Assessment of Total and Unbound Cabotegravir Pharmacokinetics Among Pregnant Women in HPTN 084
Background HPTN 084 found that long-acting cabotegravir (CAB-LA) significantly reduced the risk of HIV acquisition in women compared to tenofovir disoproxil fumarate/emtricitabine (TDF/FTC). In the HPTN 084 open label extension, participants consented to CAB-LA injections during pregnancy. A nested sub-study evaluated the pharmacokinetics of total and unbound (bioavailable) CAB among a subset of participants who…